CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex

Neuroscience Research

Volumn 70, Issue 3, 2011, Pages 334-337

  Kleijn, Jelle ^a   Cremers, Thomas I F H ^b   Hofland, Corry M ^b   Westerink, Ben H C ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

CB 1 receptor; In vivo microdialysis; Prefrontal cortex; Rat; Serotonin; SSRI

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABIS; CITALOPRAM; RIMONABANT; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ANIMALS; BENZOXAZINES; CANNABINOIDS; CITALOPRAM; DRUG INTERACTIONS; ENDOCANNABINOIDS; EXTRACELLULAR FLUID; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PREFRONTAL CORTEX; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 79957583218     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2011.03.004     Document Type: Article

References (31)

1. Allers K.A., Dremencov E., Ceci A., Flik G., Ferger B., Cremers T.I., Ittrich C., Sommer B. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J. Sex. Med. 2010, 7:1757-1767.
2. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 2001, 4:399-408.
3. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 2007, 62:1103-1110.
4. Bovasso G.B. Cannabis abuse as a risk factor for depressive symptoms. Am. J. Psychiatry 2001, 158:2033-2037.
5. Chouljian T.L., Shumway M., Balancio E., Dwyer E.V., Surber R., Jacobs M. Substance use among schizophrenic outpatients: prevalence, course, and relation to functional status. Ann. Clin. Psychiatry 1995, 7:19-24.
6. Cornelius J.R., Maisto S.A., Martin C.S., Bukstein O.G., Salloum I.M., Daley D.C., Wood D.S., Clark D.B. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict. Behav. 2004, 29:1035-1038.
7. Darmani N.A., Janoyan J.J., Kumar N., Crim J.L. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 2003, 75:777-787.
8. Fu Q., Heath A.C., Bucholz K.K., Nelson E., Goldberg J., Lyons M.J., True W.R., Jacob T., Tsuang M.T., Eisen S.A. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch. Gen. Psychiatry 2002, 59:1125-1132.
9. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., Gorzalka B.B. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J. Neurochem. 2008, 106:2322-2336.
10. Kaminer Y., Connor D.F., Curry J.F. Comorbid adolescent substance use and major depressive disorders: a review. Psychiatry (Edgmont) 2007, 4:32-43.
11. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am. J. Psychiatry 1985, 142:1259-1264.
12. Lau T., Schloss P. The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons. Eur. J. Pharmacol. 2008, 578:137-141.
13. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 51:273-279.
14. Lynskey M.T., Glowinski A.L., Todorov A.A., Bucholz K.K., Madden P.A.F., Nelson E.C., Statham D.J., Martin N.G., Heath A.C. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch. Gen. Psychiatry 2004, 61:1026-1032.
15. Miller-Johnson S., Lochman J.E., Coie J.D., Terry R., Hyman C. Comorbidity of conduct and depressive problems at sixth grade: substance use outcomes across adolescence. J. Abnorm. Child Psychol. 1998, 26:221-232.
16. Moranta D., Esteban S., Garcia-Sevilla JA Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:61-72.
17. Nakazi M., Bauer U., Nickel T., Kathmann M., Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 361:19-24.
18. Osher F.C., Drake R.E., Noordsy D.L., Teague G.B., Hurlbut S.C., Biesanz J.C., Beaudett M.S. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J. Clin. Psychiatry 1994, 55:109-113.
19. Paxinos G., Watson C. The Rat Brain in stereotaxic coordinates 2007, Academic Press.
20. Raphael B., Wooding S., Stevens G., Connor J. Comorbidity: cannabis and complexity. J. Psychiatr. Pract. 2005, 11:161-176.
21. Rea K., Folgering J., Westerink B.H.C., Cremers T.I.F.H. Alpha 1-adrenoceptors modulate citalopram-induced serotonin release. Neuropharmacology 2010, 58:962-971.
22. Rey J.M., Tennant C.C. Cannabis and mental health. BMJ 2002, 325:1183-1184.
23. Rey J.M., Sawyer M.G., Raphael B., Patton G.C., Lynskey M. Mental health of teenagers who use cannabis. Results of an Australian survey. Br. J. Psychiatry 2002, 180:216-221.
24. Riggs P.D., Baker S., Mikulich S.K., Young S.E., Crowley T.J. Depression in substance-dependent delinquents. J. Am. Acad. Child Adolesc. Psychiatry 1995, 34:764-771.
25. Rowe M.G., Fleming M.F., Barry K.L., Manwell L.B., Kropp S. Correlates of depression in primary care. J. Fam. Pract. 1995, 41:551-558.
26. Sagredo O., Ramos J.A., Fernandez-Ruiz J., Rodriguez M.L., de Miguel R. Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 372:313-317.
27. Subramaniam G.A., Stitzer M.A., Clemmey P., Kolodner K., Fishman M.J. Baseline depressive symptoms predict poor substance use outcome following adolescent residential treatment. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1062-1069.
28. Swofford C.D., Kasckow J.W., Scheller-Gilkey G., Inderbitzin L.B. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr. Res. 1996, 20:145-151.
29. Takahashi E., Katayama M., Niimi K., Itakura C. Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur. J. Pharmacol. 2008, 589:149-156.
30. Troisi A., Pasini A., Saracco M., Spalletta G. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 1998, 93:487-492.
31. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., Nomikos G.G. The CB1 receptor antagonist SR 141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 2003, 138:544-553.